Fast Track desig for chikungunya vaccineJuly 16, 2018
The US FDA granted Fast Track designation for a candidate vaccine against the disease caused by chikungunya virus, announced PaxVax, the developer of the vaccine.
The vaccine was licensed from the National Institute of Allergy and Infectious Diseases (NIAID) at National Institutes of Health (NIH).
The Phase 2b study of the virus-like particle (VLP) vaccine is in the process of enrolling 400 subjects to evaluate multiple dosing regimens. PaxVax expects the results in early 2019.
VLP vaccines are multi-protein structures that mimic the organization and conformation of naturally occurring viruses, but lack the viral genome. They are non-infectious. Additionally, the chikungunya VLP vaccine maintains natural epitopes to mimic natural infection.
Spreads through mosquito bites, the virus can often cause large outbreaks. In 2016 there were approximately 60,000 cases of chikungunya across India.